CA2138513A1 - Methods of inhibiting myeloperoxidase activity - Google Patents

Methods of inhibiting myeloperoxidase activity

Info

Publication number
CA2138513A1
CA2138513A1 CA002138513A CA2138513A CA2138513A1 CA 2138513 A1 CA2138513 A1 CA 2138513A1 CA 002138513 A CA002138513 A CA 002138513A CA 2138513 A CA2138513 A CA 2138513A CA 2138513 A1 CA2138513 A1 CA 2138513A1
Authority
CA
Canada
Prior art keywords
compound
formula
inhibiting
activity
myeloperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002138513A
Other languages
English (en)
French (fr)
Inventor
Andrew Lawrence Glasebrook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2138513A1 publication Critical patent/CA2138513A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002138513A 1993-12-21 1994-12-19 Methods of inhibiting myeloperoxidase activity Abandoned CA2138513A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,330 1993-12-21
US08/171,330 US5708009A (en) 1993-12-21 1993-12-21 Methods of inhibiting myeloperoxidase activity

Publications (1)

Publication Number Publication Date
CA2138513A1 true CA2138513A1 (en) 1995-06-22

Family

ID=22623358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138513A Abandoned CA2138513A1 (en) 1993-12-21 1994-12-19 Methods of inhibiting myeloperoxidase activity

Country Status (16)

Country Link
US (2) US5708009A (enExample)
EP (1) EP0664125A1 (enExample)
JP (1) JPH07242546A (enExample)
KR (1) KR950016743A (enExample)
CN (1) CN1109884A (enExample)
AU (1) AU8154394A (enExample)
CA (1) CA2138513A1 (enExample)
CZ (1) CZ322794A3 (enExample)
HU (1) HUT72314A (enExample)
IL (1) IL112047A0 (enExample)
NO (1) NO944926L (enExample)
NZ (1) NZ270184A (enExample)
PH (1) PH31556A (enExample)
RU (1) RU94044489A (enExample)
TW (1) TW272939B (enExample)
ZA (1) ZA9410096B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
EP0724879A2 (en) * 1995-02-06 1996-08-07 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiopenes for inhibiting effects of IL-6
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE60021720T2 (de) 1999-05-04 2006-06-01 Strakan International Ltd. Androgen glykoside und die androgenische aktivität davon
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP2006515616A (ja) * 2003-01-06 2006-06-01 ワイス 多発性硬化症の治療のためのエストロゲン受容体αモジュレーターの使用方法
DE602005020755D1 (de) * 2004-03-05 2010-06-02 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
CN101472926A (zh) * 2006-04-13 2009-07-01 阿斯利康(瑞典)有限公司 硫代黄嘌呤衍生物以及它们作为髓过氧化物酶抑制剂的用途
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use

Also Published As

Publication number Publication date
CZ322794A3 (en) 1995-08-16
ZA9410096B (en) 1996-06-19
RU94044489A (ru) 1996-10-20
AU8154394A (en) 1995-06-29
NO944926L (no) 1995-06-22
TW272939B (enExample) 1996-03-21
EP0664125A1 (en) 1995-07-26
NO944926D0 (no) 1994-12-19
JPH07242546A (ja) 1995-09-19
HUT72314A (en) 1996-04-29
IL112047A0 (en) 1995-03-15
KR950016743A (ko) 1995-07-20
PH31556A (en) 1998-11-03
HU9403677D0 (en) 1995-02-28
NZ270184A (en) 1999-07-29
CN1109884A (zh) 1995-10-11
US5708010A (en) 1998-01-13
US5708009A (en) 1998-01-13

Similar Documents

Publication Publication Date Title
US5521198A (en) Methods of inhibiting autoimmune diseases
US5708009A (en) Methods of inhibiting myeloperoxidase activity
US5534526A (en) Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
CA2118092A1 (en) Methods of inhibiting endometriosis
AU690595B2 (en) Method for increasing libido in post-menopausal women
EP0659413B1 (en) Inhibition of CNS problems in post-menopausal women
AU701701B2 (en) Methods of inhibiting breast disorders
US5451590A (en) Methods of inhibiting sexual precocity
US5578614A (en) Methods for inhibiting weight gain or inducing weight loss
US5512296A (en) Methods for inhibiting neuronal damage
AU690162B2 (en) Methods of inhibiting hirsutism and alopecia in women
US5719190A (en) Inhibition of myeloperoxidase activity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued